Combinations of Cytotoxic Drugs, Ionizing Radiation, and Angiogenesis Inhibitors

  • Carsten Nieder
  • Nicolaus H. Andratschke
Part of the Medical Radiology book series (MEDRAD)


Vascular Endothelial Growth Factor Clin Oncol Vascular Endothelial Growth Factor Receptor Radiat Oncol Biol Phys Antiangiogenic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abdollahi A, Hlatky L, Huber PE (2005) Endostatin: the logic of antiangiogenic therapy. Drug Resist Update 8:59–74CrossRefGoogle Scholar
  2. Abedi H, Zachary I (1997) Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 272:15442–15451PubMedCrossRefGoogle Scholar
  3. Aiello LP, Pierce EA, Foley ED et al (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92:10457–10461PubMedCrossRefGoogle Scholar
  4. Andratschke NH, Nieder C, Price RE et al (2004) Modulation of rodent spinal cord radiation tolerance by administration of platelet-derived growth factor. Int J Radiat Oncol Biol Phys 60:1257–1263PubMedCrossRefGoogle Scholar
  5. Andratschke N, Nieder C, Price RE et al (2005) Potential role of growth factors in diminishing radiation therapy neural tissue injury. Semin Oncol 32(Suppl 3):S67–S70PubMedCrossRefGoogle Scholar
  6. Ansiaux R, Baudelet C, Jordan BF et al (2005) Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11:743–750PubMedGoogle Scholar
  7. Asano M, Yukita A, Matsumoto T et al (1995) Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res 55:5296–5301PubMedGoogle Scholar
  8. Ausprunk DH, Folkman J (1977) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14:53–65PubMedCrossRefGoogle Scholar
  9. Bell C, Lynam E, Landfair DJ et al (1999) Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 35:533–542PubMedGoogle Scholar
  10. Benjamin LE, Golijanin D, Itin A et al (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159–165PubMedGoogle Scholar
  11. Bissett D, O’Byrne KJ, Pawel J von et al (2005) Phase III study of matrix metalloproteinase inhibitor prinomastat in nonsmall-cell lung cancer. J Clin Oncol 23:842–849PubMedCrossRefGoogle Scholar
  12. Borgström P, Hillan KJ, Sriramarao P, Ferrara N (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56:4032–4039PubMedGoogle Scholar
  13. Bramhall SR, Schulz J, Nemunaitis J et al (2002a) A doubleblind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167PubMedCrossRefGoogle Scholar
  14. Bramhall SR, Hallissey MT, Whiting J et al (2002b) Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86:1864–1870PubMedCrossRefGoogle Scholar
  15. Brieger J, Schroeder P, Gosepath J, Mann WJ (2005) VEGF-subtype specific protection of SCC and HUVECs from radiation induced cell death. Int J Mol Med 15:145–151PubMedGoogle Scholar
  16. Bruns CJ, Liu W, Davis DW et al (2000) Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89:488–499PubMedCrossRefGoogle Scholar
  17. Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9:777–794PubMedGoogle Scholar
  18. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389–395PubMedCrossRefGoogle Scholar
  19. Carmeliet P, Collen D (2000) Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann NY Acad Sci 902:249–262PubMedGoogle Scholar
  20. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257PubMedCrossRefGoogle Scholar
  21. Chang SM, Lamborn KR, Malec M et al (2004) Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60:353–357PubMedCrossRefGoogle Scholar
  22. Cropp G, Rosen L, Mulay M et al (1999) Pharmacokinetics and pharmacodynamics of SU5416 in a phase I, dose-escalating trial in patients with advanced malignancies. Proc Am Soc Clin Oncol 18:161a, abstact 619Google Scholar
  23. Damiano V, Melisi D, Bianco C et al (2005) Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 11:5639–5644PubMedCrossRefGoogle Scholar
  24. Davidoff AM, Leary MA, Ng CY, Vanin EF (2001) Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 36:30–36PubMedCrossRefGoogle Scholar
  25. De Gowin RL, Lewis LJ, Hoak JC et al (1974) Radiosensitivity of human endothelial cells in culture. J Lab Clin Med 84:42–48PubMedGoogle Scholar
  26. Denekamp J (1993) Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181–196PubMedGoogle Scholar
  27. DeVore RF, Fehrenbacher L, Herbst RS et al (2000) A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 19:454a. Abstract 1896Google Scholar
  28. Diaz-Gonzalez JA, Russell J, Rouzaut A et al (2005) Targeting hypoxia and angiogenesis through HIF-1alpha Inhibition. Cancer Biol Ther 4:1055–1062PubMedGoogle Scholar
  29. Dings RP, Williams BW, Song CW et al (2005) Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 115:312–319PubMedCrossRefGoogle Scholar
  30. Drevs J, Hofmann I, Hugenschmidt H et al (2000) Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819–4824PubMedGoogle Scholar
  31. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039PubMedGoogle Scholar
  32. Endrich B, Vaupel P (1998) The role of the microcirculation in the treatment of malignant tumors: facts and fiction. In: Molls M, Vaupel P (eds) Blood perfusion and microenvironment of human tumors. Springer, Berlin Heidelberg New York, pp 19–39Google Scholar
  33. Fenton BM, Paoni SF, Ding I (2004) Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res 64:5712–5719PubMedCrossRefGoogle Scholar
  34. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527–543PubMedCrossRefGoogle Scholar
  35. Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359–1364PubMedCrossRefGoogle Scholar
  36. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedGoogle Scholar
  37. Folkman J (1986) How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award lecture. Cancer Res 46:467–473PubMedGoogle Scholar
  38. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31PubMedCrossRefGoogle Scholar
  39. Fong TA, Shawver LK, Sun L et al (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99–106PubMedGoogle Scholar
  40. Frederick B, Gustafson D, Bianco C et al (2006) ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys 64:33–37PubMedCrossRefGoogle Scholar
  41. Fuks Z, Persaud RS, Alfieri A et al (1994) Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 54:2582–2590PubMedGoogle Scholar
  42. Fukumoto S, Morifuji M, Katakura Y et al (2005) Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 22:31–38PubMedCrossRefGoogle Scholar
  43. Geng L, Donnelly E, McMahon G et al (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413–2419PubMedGoogle Scholar
  44. Giantonio BJ, Catalano PJ, Meropol NJ et al (2005) Highdose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (Abstract). J Clin Oncol 23:1sGoogle Scholar
  45. Goldman CK, Kendall RL, Cabrera G et al (1998) Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95:8795–8800PubMedCrossRefGoogle Scholar
  46. Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850PubMedGoogle Scholar
  47. Gorski DH, Beckett MA, Jaskowiak NT et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378PubMedGoogle Scholar
  48. Gray LH, Conger AD, Ebert M et al (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638–648PubMedCrossRefGoogle Scholar
  49. Griffin RJ, Williams BW, Wild R et al (2002) Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 62:1702–1706PubMedGoogle Scholar
  50. Guo D, Jia Q, Song HY et al (1995) Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270:6729–6733PubMedCrossRefGoogle Scholar
  51. Gupta VK, Jaskowiak NT, Beckett MA et al (2002) Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8:47–54PubMedGoogle Scholar
  52. Haimovitz-Friedman A, Vlodavsky I, Chaudhuri A et al. (1991) Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res 51:2552–2558PubMedGoogle Scholar
  53. Hei TK, Marchese MJ, Hall EJ (1987) Radiosensitivity and sublethal damage repair in human umbilical cord vein endothelial cells. Int J Radiat Oncol Biol Phys 13:879–884PubMedGoogle Scholar
  54. Hess C, Vuong V, Hegyi I et al (2001) Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85:2010–2016PubMedCrossRefGoogle Scholar
  55. Huber PE, Bischof M, Jenne J et al (2005) Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65:3643–3655PubMedCrossRefGoogle Scholar
  56. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  57. Im SA, Gomez-Manzano C, Fueyo J et al (1999) Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59:895–900PubMedGoogle Scholar
  58. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRefGoogle Scholar
  59. Jakeman LB, Winer J, Bennett GL et al (1992) Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89:244–253PubMedCrossRefGoogle Scholar
  60. Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in firstline metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–3705PubMedCrossRefGoogle Scholar
  61. Kal HB, Struikmans H, Gebbink MF, Voest EE (2004) Response of rat prostate and lung tumors to ionizing radiation combined with the angiogenesis inhibitor AMCA. Strahlenther Onkol 180:798–804PubMedCrossRefGoogle Scholar
  62. Karkkainen MJ, Petrova TV (2000) Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19:5598–5605PubMedCrossRefGoogle Scholar
  63. Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515PubMedCrossRefGoogle Scholar
  64. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436PubMedCrossRefGoogle Scholar
  65. Kerbel RS, Viloria-Petit A, Okada F, Rak J (1998) Establishing a link between oncogenes and tumor angiogenesis. J Mol Med 4:286–295Google Scholar
  66. Kermani P, Leclerc G, Martel R, Fareh J (2001) Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: the role of VEGF(165). Int J Radiat Oncol Biol Phys 50:213–220PubMedCrossRefGoogle Scholar
  67. Kim KJ, Li B, Winer J, Armanini M et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844PubMedCrossRefGoogle Scholar
  68. Koukourakis MI (2001) Tumour angiogenesis and response to radiotherapy. Anticancer Res 21:4285–4300PubMedGoogle Scholar
  69. Kozin SV, Boucher Y, Hicklin DJ et al (2001) Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 6:39–44Google Scholar
  70. Kozin SV, Boucher Y, Tomaso E di et al (2002) Glomerulopathy in mice treated with whole-body irradiation and VEGFR2-blocking antibody. 49th Annual Meeting of the Radiation Research Society, Reno, Nevada, 2002, P08–P65Google Scholar
  71. Kuenen BC, Rosen L, Smit EF et al (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657–1667PubMedCrossRefGoogle Scholar
  72. Kumar P, Benedict R, Urzua F et al (2005) Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Invest 85:756–767PubMedCrossRefGoogle Scholar
  73. Laird AD, Vajkoczy P, Shawver LK et al (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152–4160PubMedGoogle Scholar
  74. Lee CG, Heijn M, Tomaso E di et al (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565–5570PubMedGoogle Scholar
  75. Leighl NB, Paz-Ares L, Douillard JY et al (2005) Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada Clinical Trials Group Study BR.18. J Clin Oncol 23:2831–2839PubMedCrossRefGoogle Scholar
  76. Leith JT, Papa G, Quaranto L, Michelson S (1992) Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin. Br J Cancer 66:345–348PubMedGoogle Scholar
  77. Li J, Huang S, Armstrong EA et al (2005) Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 62:1477–1485PubMedCrossRefGoogle Scholar
  78. Lin P, Sankar S, Shan S et al (1998) Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9:49–58PubMedGoogle Scholar
  79. Machein MR, Risau W, Plate KH (1999) Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther 10:1117–1128PubMedCrossRefGoogle Scholar
  80. Maggiorella L, Wen B, Frascogna V et al (2005) Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. Anticancer Res 25:4357–4362PubMedGoogle Scholar
  81. Margolin K, Gordon MS, Holmgren E et al. (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19:851–856PubMedGoogle Scholar
  82. Marx GM, Steer CB, Harper P et al (2002) Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol 20:1446–1448PubMedGoogle Scholar
  83. McDonnell CO, Holden G, Sheridan ME et al (2004) Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model. J Surg Res 116:19–23PubMedCrossRefGoogle Scholar
  84. Mendel DB, Schreck RE, West DC et al (2000) The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6:4848–4858PubMedGoogle Scholar
  85. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799PubMedCrossRefGoogle Scholar
  86. Murata R, Nishimura Y, Hiraoka M (1997) An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 37:1107–1113PubMedCrossRefGoogle Scholar
  87. Ning S, Laird D, Cherrington JM, Knox SJ (2002) The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157:45–51PubMedCrossRefGoogle Scholar
  88. Okada F, Rak JW, Croix BS et al (1998) Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 95:3609–3614PubMedCrossRefGoogle Scholar
  89. O’Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689–692PubMedCrossRefGoogle Scholar
  90. O’Reilly MS, Boehm T, Shing Y et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285PubMedCrossRefGoogle Scholar
  91. Parry TJ, Cushman C, Gallegos AM et al (1999) Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 27:2569–257PubMedCrossRefGoogle Scholar
  92. Presta LG, Chen H, O’Connor SJ et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599PubMedGoogle Scholar
  93. Prewett M, Huber J, Li Y et al (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209–5218PubMedGoogle Scholar
  94. Rockwell P, O’Connor WJ, King K et al (1997) Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 94:6523–6528PubMedCrossRefGoogle Scholar
  95. Rosen LS (2002) Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9(2 Suppl):36–44PubMedGoogle Scholar
  96. Rosen L, Mulay M, Mayers A et al (1999) Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 18:161a, abstract 618Google Scholar
  97. Sandler AB, Gray R, Brahmer J et al (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial — E4599 (Abstract). J Clin Oncol 23:2sGoogle Scholar
  98. Schuuring J, Bussink J, Bernsen H et al (2005) Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int J Radiat Oncol Biol Phys 61:529–534PubMedCrossRefGoogle Scholar
  99. Shaheen RM, Davis DW, Liu W et al (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59:5412–5416PubMedGoogle Scholar
  100. Shi W, Siemann DW (2005) Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res 25:3899–3904PubMedGoogle Scholar
  101. Shinohara ET, Cao C, Niermann K et al (2005) Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24:5414–5422PubMedCrossRefGoogle Scholar
  102. Siemann DW, Rojiani AM (2005) The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 62:846–853PubMedCrossRefGoogle Scholar
  103. Siemann DW, Warrington KH, Horsman MR (2000) Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiother Oncol 57:5–12PubMedCrossRefGoogle Scholar
  104. Sparano JA, Bernardo P, Stephenson P et al (2004) Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 22:4683–4690PubMedCrossRefGoogle Scholar
  105. Stadler WM, Cao D, Vogelzang NJ et al (2004) A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 10:3365–3370PubMedCrossRefGoogle Scholar
  106. Stoletov KV, Ratcliffe KE, Spring SC, Terman BI (2001) NCK and PAK participate in the signaling pathway by which vascular endothelial growth factor stimulates the assembly of focal adhesions. J Biol Chem 276:22748–22755PubMedCrossRefGoogle Scholar
  107. Stopeck A (2000) Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Proc Am Soc Clin Oncol 19:206a, abstract 802Google Scholar
  108. Sun J, Wang DA, Jain RK et al (2005) Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 24:4701–4709PubMedCrossRefGoogle Scholar
  109. Szczylik C, Eisen T, Stadler WM et al (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (Abstract). J Clin Oncol 23:1093sGoogle Scholar
  110. Teicher BA, Sotomayor EA, Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702–6704PubMedGoogle Scholar
  111. Thula TT, Schultz G, Tran-Son-Tay R, Batich C (2005) Effects of EGF and bFGF on irradiated parotid glands. Ann Biomed Eng 33:685–695PubMedCrossRefGoogle Scholar
  112. Tomaso E di, Capen D, Haskell A et al (2005) Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res 65:5740–5749PubMedCrossRefGoogle Scholar
  113. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K (2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60:203–212PubMedGoogle Scholar
  114. Wachsberger PR, Burd R, Marero N et al (2005) Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11:835–842PubMedGoogle Scholar
  115. Wedge SR, Ogilvie DJ, Dukes M et al (2000) ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60:970–975PubMedGoogle Scholar
  116. Williams KJ, Telfer BA, Brave S et al (2004) ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10:8587–8593PubMedCrossRefGoogle Scholar
  117. Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563PubMedGoogle Scholar
  118. Witte L, Fuks Z, Haimovitz-Friedman A et al (1989) Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells. Cancer Res 49:5066–5072PubMedGoogle Scholar
  119. Wood JM, Bold G, Buchdunger E et al.(2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178–2189PubMedGoogle Scholar
  120. Wright EA, Howard-Flanders P (1957) The influence of oxygen on the radiosensitivity of mammalian tissues. Acta Radiol 48:26–32PubMedCrossRefGoogle Scholar
  121. Xu L, Tong R, Cochran DM, Jain RK (2005) Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 65:5711–5719PubMedCrossRefGoogle Scholar
  122. Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248PubMedCrossRefGoogle Scholar
  123. Yuan F, Chen Y, Dellian M et al (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765–14770PubMedCrossRefGoogle Scholar
  124. Zhang Y, Griffith EC, Sage J et al (2000) Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA 97:6427–6432PubMedCrossRefGoogle Scholar
  125. Zips D, Baumann M (2003) Anti-VEGF strategies in combination with radiotherapy. In: Nieder C, Milas L, Ang KK (eds) Modification of radiation response. Springer, Berlin Heidelberg New York, pp 179–188Google Scholar
  126. Zips D, Hessel F, Krause M et al (2005) Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 61:908–914PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Carsten Nieder
    • 1
  • Nicolaus H. Andratschke
    • 1
  1. 1.Department of Radiation OncologyKlinikum rechts der Isar der Technischen Universität MünchenMünchenGermany

Personalised recommendations